公开(公告)号：US20230416357A1

公开(公告)日：2023-12-28

申请号：US18253240

申请日：2021-12-06

Applicant: UCB BIOPHARMA SRL

Inventor： Joseph Michael David RASTRICK ,  John Paul SILVA ,  Kerry Louise TYSON ,  Peter Charles ELLIOTT ,  Seppe Frans Roman LEYSEN ,  Zainab AHDASH

IPC: C07K16/24

CPC classification number: C07K16/244 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/34 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/33

Abstract: The present invention relates to antibodies binding to IL22 and inhibiting its interaction with one or more of its natural ligands Specific examples of such antibodies are provided. The therapeutic uses of the antibodies and methods of generating such C are also provided.

公开(公告)号：US20230070261A1

公开(公告)日：2023-03-09

申请号：US17759988

申请日：2021-02-01

Applicant: UCB BIOPHARMA SRL

Inventor： Neesha DEDI ,  Peter Charles ELLIOTT ,  Seppe Frans Roman LEYSEN ,  Sean MASON ,  David James MCMILLAN ,  Gillian Claire NESS ,  Niccolo PENGO ,  Martin Anthony REDHEAD ,  Alison TURNER ,  Kerry Louise TYSON

IPC: C07K16/40

Abstract: The present invention relates to antibodies which bind and inhibit KLK5 and methods of using the same to treat diseases caused by KLK5 imbalance. In particular, the present invention relates to inhibitory anti-KLK5 antibodies and their use in the treatment of Netherton disease, atopic dermatitis and cancer.

公开(公告)号：US20240067758A1

公开(公告)日：2024-02-29

申请号：US18255213

申请日：2021-12-06

Applicant: UCB BIOPHARMA SRL

Inventor： Joseph Michael David RASTRICK ,  John Paul SILVA ,  Daniel John LIGHTWOOD ,  Ralph ADAMS ,  Roger Thomas PALFRAMAN ,  Kerry Louise TYSON ,  Peter Charles ELLIOTT ,  Seema MAYANK ,  Andrea Julie CROSBY ,  Emily Mary Cairistine BARRY ,  Seppe Frans Roman LEYSEN ,  Zainab AHDASH

IPC: C07K16/46 ,  C12N15/63 ,  A61P17/00

CPC classification number: C07K16/468 ,  C12N15/63 ,  A61P17/00 ,  C07K2317/31 ,  C07K2317/76 ,  C07K2317/565 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/14

Abstract: The present invention relates to antibodies binding to IL13 and IL22. The invention provides novel multi-specific antibodies that bind to both IL13 and IL22 and compositions comprising an antibody that binds to IL13 and an antibody that binds to IL22. The invention further relates to therapeutic uses of the combination of anti-IL13 and anti-IL22 antibodies and multi-specific antibodies that bind to both IL13 and IL22.

公开(公告)号：US20230075753A1

公开(公告)日：2023-03-09

申请号：US17759986

申请日：2021-02-01

Applicant: UCB BIOPHARMA SRL

Inventor： Neesha DEDI ,  Peter Charles ELLIOTT ,  Seppe Frans Roman LEYSEN ,  Sean MASON ,  David James MCMILLAN ,  Gillian Claire NESS ,  Niccolo PENGO ,  Martin Anthony REDHEAD ,  Alison TURNER ,  Kerry Louise TYSON

IPC: C07K16/40 ,  C12N15/63 ,  A61P17/00

Abstract: The present invention relates to antibodies which bind and inhibit KLK5 and methods of using the same to treat diseases caused by KLK5 imbalance. In particular, the present invention relates to inhibitory antibodies binding KLK5 and their use in the treatment of Netherton disease, atopic dermatitis and cancer.